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Abstract
Ixazomib-Revlimid-Dexamethasone is an all-oral treatment protocol for multiple myeloma with a manageable tolerability profile
which was available through a named patient program for Hungarian patients from December 2015 to April 2017. We analyzed
the clinical characteristics and survival of 77 patients treated at 7 centers within this program. The majority of patients responded,
we found complete response in 9, very good partial response in 8, partial response in 32, minor response or stable disease in 13
and progressive disease in 11 patients. Progression free survival was 11.4 months. There was a trend of longer progression free
survival in those with 1 vs. >1 prior treatment, with equally good effectivity in standard risk and high risk cytogenetic groups. The
adverse events were usually mild, none leading to permanent drug interruptions. There were 5 fatalities: 3 infections and 2
pulmonary embolisms. Our real word data support the use of Ixazomib-Revlimid-Dexamethasone as a highly effective and well
tolerated oral treatment protocol for relapsed myeloma.
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Introduction
It was 15 years ago that introduction of the intravenous pro-
teasome inhibitor (PI) bortezomib revolutionized the treat-
ment of multiple myeloma, soon followed by the approval
of lenalidomide for the same disease. Ixazomib, however, is
the first oral PI that showed high efficacy and safety for the
treatment of relapsed and/or refractory multiple myeloma in
the TOURMALINE MM1 trial in combination with
lenalidomide and dexamethasone (IRD) leading to its FDA
and subsequent EMA approval. Its indication stands as:
relapsed/refractory multiple myeloma (MM) that have re-
ceived at least one prior therapy [1]. IRD is an all-oral treat-
ment protocol with a manageable tolerability profile in
patients with MM including those with high cytogenetic
risk [2, 3].
Nevertheless, clinical trials are significantly different from
real world use of therapies in many aspects including less
rigorous patient selection, greater flexibility with dosing and
country specific funding restrictions. This makes reporting of
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real world data very important for clinicians. Regarding the
IRD triplet combination, available real world data are current-
ly very limited [4–6].
Following its FDA approval, fromDecember 2015 to April
2017 IRD treatment was available for Hungarian patients with
relapsed MM treated with 1–3 prior lines of therapy through a
Named Patient Program (NPP) by Takeda Parmaceuticals.
Inclusion criteria followed that of the pivotal trial [1], and
are summarized in Table 1. Protocol treatment continued until
progression or death; several patients are still taking the
medications.
Aims and Methods
The aim of this retrospective study was to evaluate the efficacy
and safety of IRD in the real world practice in a retrospective
analysis using case records of patients taking part in the
Hungarian Ixazomib NPP. Its scope was to analyze interna-
tional staging system (ISS) and fluorescent in situ hybridiza-
tion (FISH) status, response rate, progression free survival
(PFS), treatment duration, adverse events (AEs), as well as
dose modifications and treatment discontinuations.
Patients who have not completed at least one full cycle
were excluded. Patients were continued to be followed up if
treatment was stopped due to side effects, administrative or
regulatory reasons, but were censored with that date if a new
therapeutic line was started without fulfilling the IMWG
criteria for progressive disease. Response criteria (complete
response [CR], very good partial response [VGPR], partial
response [PR], no response [NR], and progressive disease
[PD]) and survival measures (progression-free survival
[PFS] and overall survival [OS]) were defined according to
published International Myeloma Working Group guidelines
[7]. Statistical analyses were performed using the SPSS (ver-
sion 20.0) software package. The way how FISH testing was
performed varied with no plasma cell selection in the majority
of the centers. There was no consensus regarding the probes
used but those for 17p deletion, translocations (11;14), (4;14)
and (14;16) and 1q amplification were generally part of the
set. FISH results were available in 54 out of the 77 patient. For
the purpose of this study, patients with t(4;14), t(14;16), 1q
amplification and del(17p) were grouped together as a high
risk cohort.
The study was approved by the Hungarian National Ethics
Committee, the patients provided full informed consent, and
treatment inclusion of each and every patient was individually
approved by the Hungarian National Institute of Pharmacy.
Results
Patient Characteristics
77 patients entered the program and were treated at 7 centers,
their clinical characteristics are presented in Table 2. Three
cases were excluded from the efficacy analyses as they had
not completed a single full cycle of therapy. Patients were
younger than the usual myeloma patient at this stage (median
Table 1 Eligibility criteria of the ixazomib named patient program
Patient is = > 18 years of age
Patient is diagnosed with multiple myeloma according to standard criteria
Patient has received 1 to 3 prior lines of therapy
Patient is in biochemical or symptomatic relapse and is not on an active
anti-myeloma therapy (except for steroids) at the time of this applica-
tion
Next planned therapy for the patient is ixazomib in combination with
lenalidomide and dexamethasone
Patient is not refractory to lenalidomide or a proteasome inhibitor, or was
not refractory to lenalidomide or proteasome inhibitor-based therapy at
any line.
Absolute neutrophil count = > 1000/mm3 and platelet count
= > 75,000/mm3;
Total bilirubin <= 1.5 x upper limit of normal;
Alanine aminotransferase and aspartate aminotransferase <= 3 x upper
limit of normal;
Calculated creatinine clearance = > 30 mL/min
Patient has an ECOG performance status score of 0, 1 or 2
Both males and females have agreed to use an effective contraception
method during and for 90 days following treatment.
Table 2 Patient characteristics prior to start of the IRD treatment. This
table includes 77 patients, however 3 of them who did not complete the
first course were excluded from the efficacy analyses
n (%)
All cases 77
Had <1 cycles of IRD 3 (3.8%)
Sex (M/F) 42 (54%)/35 (46%)
Number of prior lines (1, 2, 3) 21 (27%), 27 (35%), 30 (39%)
Prior Bortezomib 76 (99%)
Thalidomide 77 (99%)
Transplantation 45 (58%)
Refractory to last line 2 (2.6%)
ISS 1 28 (36%)
2 9 (11%)
3 17 (22%)
not performed 23 (30%)
FISH high risk 21 (27%)
standard risk 33 (43%)
not performed 23 (30%)
Mean number of IRD cycles 8.3
Ixazomib dose reduction required 9 (11%)
Permanent interruption due to AEs 5 (6.5%)
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age was 66 years), and were heavily pretreated. The median
line of prior treatment was 2, the percentage of patients having
had 1, 2 and 3 prior cycles were 29, 34 and 37%, respectively.
Except for one patient, all had both IMiD and PI pretreatment
in various combinations depending on the era when it was
initiated. In some patients prior treatment lines spanned over
several years, others were refractory and therefore exhausted
their options quickly.
The availability of lenalidomide at the time of this program
was limited, and this affected the number of potential patients.
Lenalidomide was only funded through an individual patient
funding scheme which required 3 monthly renewals that were
not automatically granted. NPP applications were filed usually
for patients who have run out of other options, or had side
effects limiting the reuse of thalidomide or bortezomib. This
explains why the number of prior lines is higher in this cohort
compared to others. Failure to secure lenalidomide ac-
cess for the subsequent cycles has led to protocol inter-
ruption in some cases.
Adverse Events
According to the reported number of AEs (Table 3) IRD treat-
ment was well tolerated, AEs above grade 1–2 were rare. The
most common AEs were hematologic toxicities (mostly
thrombocytopenia) and infections. Five fatalities were record-
ed, 3 infections (2 pneumonias and 1 neutropenic sepsis) and 2
thrombotic events (both of them were pulmonary embolisms,
as prophylaxis for one had aspirin, the other low molecular
weight heparin but was non-compliant).
There were no permanent drug interruptions due to AEs,
except the 5 fatal cases. In 3 patients, however, IRD triplet
treatment was stopped prematurely due to logistic reasons: 2
patients (1 in PR and 1 in VGPR) stopped ixazomib and car-
ried on lenalidomide maintenance only, and the third with
stable disease switched to a new protocol.
Ixazomib dose reduction from 4 to 3 mg weekly dose hap-
pened in 9 patients, who then could continue on the protocol.
Reasons were mostly thrombocytopenia and diarrhea. Further
dose reduction to 2.3 mg was only necessary in one
case. Data regarding lenalidomide dose reductions and
colony stimulating factor use were not collected, but
these were both utilized in every participating center, accord-
ing to standards of care.
Efficacy
Among the 74 patients who completed at least one cycle of
treatment, IRD was effective in the majority of patients. The
best response was CR in 9, VGPR in 8, PR in 32,MR or SD in
13 and PD occurred in 11 patients, one patient had no formal
disease re-assessment. Response according to ISS, FISH and
number of prior lines of treatment is presented on Fig. 1.
After 12.5 months median follow up and 39% of patients
still on treatment, the calculated PFS was 11.4 months
(Fig. 2a). There was a trend of longer PFS in those with 1
vs. >1 prior treatment (p = 0.074, Fig. 2b), but there was no
significant difference between standard and high risk FISH
patients and the 3 ISS categories (Fig. C, D). However, the 3
cases where deletion 17p was demonstrated at the time of
relapse (clonal evolution) fared very poorly. Similarly, in cases
of clinically aggressive disease, such as plasma cell leukemia
(PCL) and extramedullary disease (EMD) IRD was less effec-
tive (data not shown).
Discussion
There are plenty of differences between the Hungarian cohort
and the published TOURMALINE MM1 trial data highlight-
ing some of the typical differences between a highly selected
trial population and real life patients [1].
A recent reviewmerged the Czech (n = 57) the British (n =
46) and the Greek (n = 35) NPP data, and published their
results (n = 138) [4]. They also excluded patients who have
not completed at least one cycle. In this group, the median age
was 68 years compared to 66 in our patients, M/F ratio was 85/
53, with ECOG 0–1: 71.8% and ECOG 2–3: 27.2% of pa-
tients. The median number of previous therapies was 1.5
(range: 1–7) which is less than in our group (median 2). In
Table 3 Adverse events
Grade 1–2 n (%) Grade 3 n (%) Grade 4 n (%) Grade 5 n (%)
Neutropenia 7 (9.1%) 6 (7.8%)
Anemia 2 (2.7%) 4 (5.2%)
Thrombocytopenia 8 (10.3%) 4 (5.2%) 2 (2.6%)
Infection 10 (12.9%) 4 (5.2%) 3 (3.8%)
Diarrhea 7 (9.1%) 1 (1.3%)
Skin rash 2 (2.7%)
Thromboembolism 2 (2.7%)
Cardiology 1 (1.3%) 1 (1.3%)
All 37 (48.1%) 22 (28.6%) 5 (6.5%)
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this group 50.0% of patients had received one line of prior
treatment, 30.4% two lines, 14.5% three lines and 5.1% had
received 4–7 prior lines of anti-myeloma therapies. The PI
pre-treatment was very frequent (94.2%) however only
59.4% of these patients had prior IMiD, and 26.1% had autol-
ogous transplantation (ASCT). Our group was more heavily
pretreated, with virtually all patients having had both PI and
IMiD, and 58% had prior ASCT.
The explanation for the significantly higher number of pre-
vious treatments with the Hungarian NPP is clear: at the time
of this program the health authorities would not have funded
lenalidomide without prior utilization of both thalidomide and
bortezomib and also required the demonstration of a reason
why retreatment with one of themwas not feasible. As a result
lenalidomide was rarely used at first relapse at the time when
this program began.
Patient-reported health-related quality of life was a second-
ary endpoint of TOURMALINE trial, which demonstrated
that addition of ixazomib to lenalidomide-dexamethasone
(Rd) significantly improved efficacy while quality of life
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Fig. 2 Progression free survival (PFS) of NPP patients. (a) PFS of all
patients, (b) PFS according to prior lines, (c) ISS, (d) FISH risk status.
There was a trend of longer PFS in those with 1 vs >1 prior treatment
(p = 0.074). Importantly there was no significant difference between stan-
dard risk and high risk FISH and ISS patients
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Fig. 1 Response rate according to the number of prior treatments. There
are numerically more CRs in patients with less prior treatment, but the
differences are not significant
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was maintained [8]. Also exposure-adjusted rates of hospital-
ization were similar between the ixazomib-Rd and placebo-Rd
arms [9, 10].
In the Czech-UK-Greek cohort the median follow-up was
9.1 months, and the median treatment duration 7.2 months,
which is similar to our findings. 10.8% of patients reached
sCR/CR, 18.5% VGPR, 39.2% PR, 4,6% MR, 10.0% SD
and 16.9% PD, which is very similar to what we have found.
The ORR (≥PR) was estimated at 68.5% in the overall popu-
lation; 76.6% in patients receiving IRD as second line, 64.3%
in those as third line and 55% in those beyond third line, again
similar to the results of the Hungarian cohort (78.9, 66.6, 59.2
in the same groups).
Similarly to our findings, treatment discontinuation rate
was low (13.7%) in the Czech-UK-Greek cohort.
Interestingly, 28.3% of their patients experienced peripheral
neuropathy, while in our study significant worsening or newly
developing neuropathy was not reported during IRD. Data
regarding preexisting neuropathy was not collected.
In this study by Terpos and coworkers, the estimated median
PFS was 27.6 months that is significantly better than what we
found, but also better than the response level the pivotal
TOURMALINE study demonstrated (20.6 months). In our pa-
tients with 12.5 months median follow up and 39% of patients
still on treatment, the calculated PFS was approximately 1 year
(11.4 months). The PFS, however, of those patients who reached
at least stable disease was 16.6 months. Importantly, the effect of
the known prognostic markers (FISH, ISS) was not significantly
influencing the PFS, although, patients with high risk clinical
features (plasma cell leukemia, extramedullary disease) had poor
outcome. In this regard our data support the TOURMALINE
study results that showed equally good effectivity in LR and
HR cytogenetic groups. This finding is probably related to the
prolonged PI exposure that is not easy to deliver with parenteral
drugs. There was a trend of longer PFS in patients with only one
prior line of treatment compared to those with two or three lines.
Probably as a consequence of the more prior treatment
lines, the proportion of high risk patients were enriched in
the Hungarian cohort. Terpos et al. did not report ISS and
FISH findings, but if our patient cohort is compared to the
TOURMALINE trial patients, we can demonstrate signifi-
cantly more ISS 3 and HR FISH patients in our group [2, 11].
Why did we enter a lot of high risk patients into this pro-
gram? On the one hand, at the time of the NPP daratumumab
and carfilzomib were not available in Hungary and ixazomib
was an attractive third agent to add to lenalidomide especially
as it demonstrated good efficacy in HR patients in the
TOURMALINE trial in which many of the Hungarian centers
actually participated [11].
Additionally, entering to the program was very quick
through online registration, therefore rapid disease progres-
sion was not an obstacle. As opposed to this, in clinical trials
due to the many requirements needed to fulfill during
screening and the required drug washout periods, patients
can be excluded from enrollment when there is an urgent need
to start effective treatment.
These reasons probably explain the shorter PFS of the
Hungarian NPP cohort when compared to the Czech-UK-
Greek NPP cohort and the TOURMALINE data. In our dataset
less than a third of patients were treated at first relapse, whereas
in the TOURMALINE trial the majority were included in this
clinical situation. Additionally, in the TOURMALINE trial on-
ly 21% had high risk cytogenetics which was present in 38% in
our patient cohort. This fact probably accounts for the shorter
PFS observed in our more heavily pretreated patient group.
We conclude that IRD proved to be a safe and effective treat-
ment option for real-life relapsed/refractory MM patients in our
country. Compared to the TOURMALINE study results, the PFS
of our cohort is somewhat inferior that is not unusual when real
life patient data are compared to randomized controlled study
results. Our NPP results further highlight the differences between
patients treated in routine practice and those treated in clinical
trials, however, fully confirm the safety and efficacy of the
ixazomib-lenalidomide-dexamethasone all-oral combination in
relapsed/refractory multiple myeloma. We believe that an all-
oral salvage regimen such as IRD remains a valid option for
the treatment of MM patients even in light of possibly newer
and more effective but parenteral drug combinations [12] as
this combination requires less frequent outpatient visits
and allows patients to maintain their usual lifestyle.
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